What NervGen has said publicly about RESTORE, in the order it was released, alongside each change to the registry record. Sites are notified here at the same time as the public.
Press release confirming the first participant in RESTORE. The link will be added here the day it is issued, together with suggested wording sites can use for local enquiries.
ClinicalTrials.gov will be updated to reflect that the study is recruiting and to list participating locations. No site action is required.
A review of the NVG-291 program, including the nonclinical and translational foundation, clinical data to date, perspectives from the spinal cord injury community, and the design and rationale of RESTORE.
Includes the RESTORE update: site selection finalized with a focus on neurorehabilitation hospitals and clinics in the United States and Canada, and screening expected to begin in September 2026.
Alignment with the FDA on the study parameters of RESTORE, a 16-week registrational study of NVG-291 in chronic tetraplegia, with GRASSP Quantitative Prehension at Week 12 as the primary endpoint.